查看购物车
  • Traditional Chinese
  • English
  • Japanese
遗传性血管性水肿市场—按治疗类型和地区分類的全球和区域分析—分析与预测（2025-2035）
市场调查报告书
商品编码
1734252

遗传性血管性水肿市场—按治疗类型和地区分類的全球和区域分析—分析与预测（2025-2035）

Hereditary Angioedema Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

全球遗传性血管性水肿市场目前正处于其生命週期的成长阶段。

这一阶段的特点是治疗选择越来越多，包括获得监管部门核准的新型生物疗法和预防疗法。人们对遗传性血管性水肿的认识不断提高、诊断方法的改进以及 C1 酯酶抑制剂和缓激肽受体拮抗剂等先进治疗药物的引入正在推动市场扩张。此外，对个人化医疗和预防医疗的日益关注也促进了市场的成长。儘管治疗费用高和患者人数有限等挑战依然存在，但治疗方案的持续创新和市场进入的扩大预计将在未来几年维持市场成长。

影响

  • 预计遗传性血管性水肿治疗需求的不断增长将在 2025-2035 年预测期内支持全球遗传性血管性水肿市场的成长。
  • 由于诊断技术的进步、创新治疗方法的市场推出以及患者和医疗保健提供者意识的提高，全球遗传性血管性水肿市场预计将显着增长。

由于其先进的医疗保健基础设施、高盛行率以及对该疾病的认识不断提高，预计北美将在预测期内主导全球遗传性血管性水肿市场。该地区还拥有良好的监管地位和强大的製药公司，为有效治疗方法的普及提供了便利，推动了全球遗传性血管性水肿市场的成长。

近期动态

  • 监管活动：2025 年 2 月，EMA 额外批准 TAKIHIRO（通用名：lanadelumab），用于 2 mL预填充笔，为患有遗传性血管性水肿 (HAE) 的青少年（12 岁及以上）和成年患者进行皮下核准。
  • 监管活动 2025 年 2 月，CSL Behring 在日本获得核准，可使用 Andenbry（galadacimab）皮下注射 200 毫克笔用于预防急性遗传性血管性水肿发作。
  • 监管活动 2025 年 1 月，KalVista Pharmaceuticals, Inc. 的 sevetralstat 获得厚生劳动省颁发的孤儿药称号。
  • 监管活动 2024 年 11 月，FDA 接受了 Ionis Pharmaceuticals 的 donidalorsen新药认证申请，用于预防性治疗遗传性血管性水肿。

需求——驱动因素与限制因素

推动全球遗传性血管性水肿市场的关键因素是：

  • 提高认识和早期诊断
  • 治疗方案的持续进步
  • 改进的基因检测和诊断
  • 遗传性血管性水肿盛行率不断上升

由于以下挑战，全球遗传性血管性水肿市场预计还将面临一些限制：

  • 医疗费用高昂
  • 开发中地区获取治疗的挑战

产品/创新策略：全球遗传性血管性水肿市场的产品发布和创新专注于推进治疗方案以改善患者护理。这些创新旨在提高治疗方法效果并简化疾病的检测和管理。市场上的主要参与企业如 Ionis Pharmaceuticals、工业和 CSL Behring 都参与开发遗传性血管性水肿的治疗方法。

竞争策略：主要关注全球遗传性血管性水肿市场领导者的公司正在不断透过创新治疗方法更新产品系列以保持竞争力。它对主要参与者进行了详细的竞争基准化分析，深入了解了这些公司在产品供应、市场占有率和创新方面的比较。透过这种基准化分析，读者可以清楚地了解市场格局和主要企业的地位。此外，包括伙伴关係、协议和联盟在内的综合竞争策略可协助读者发现市场中尚未开发的商机。

主要市场参与企业及竞争格局

公司简介是根据从主要专家收集的资讯以及透过分析公司覆盖范围、产品系列和市场渗透率来选择的。

本报告研究了全球遗传性血管性水肿市场，并概述了市场以及治疗类型、地理位置和公司概况的趋势。

目录

执行摘要

第一章全球遗传性血管性水肿市场：产业展望

  • 市场概况与生态系统
  • 市场趋势
  • 遗传性血管性水肿的流行病学分析
    • 按地区
  • 临床试验
    • 爱别
    • 依赞助商类型
  • 监管状况/合规性
    • 美国法律要求与框架
    • 欧盟法律要求和框架
    • 亚太地区的法律要求与框架
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球遗传性血管性水肿市场（依治疗类型划分），百万美元，2023-2035 年

  • C1酯酶抑制剂
  • 缓激肽B2受体拮抗剂
  • 激肽释放酶抑制剂
  • 其他的

3. 全球遗传性血管性水肿市场（按地区划分），百万美元，2023-2035 年

  • 北美洲
  • 欧洲
  • 亚太地区

4. 全球遗传性血管性水肿市场竞争基准化分析与公司概况

  • 竞争格局
    • 各公司主要策略及发展
    • 关键进展
  • 公司简介
    • Takeda Pharmaceutical Company Limited
    • CSL Behring
    • Ionis Pharmaceuticals, Inc.
    • Pharming Group
    • BioCryst Pharmaceuticals
    • KalVista Pharmaceuticals
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • Octapharma

第五章调查方法

Product Code: BHL2879SA

Market Lifecycle Stage

The global hereditary angioedema market is currently in the growth stage of its lifecycle. This phase is characterized by an increasing number of treatment options, including novel biologic therapies and prophylactic treatments, which are gaining regulatory approvals. The market is experiencing expansion driven by the rising awareness of hereditary angioedema, improved diagnostic methods, and the introduction of advanced therapies such as C1 esterase inhibitors and bradykinin receptor antagonists. Additionally, the growing focus on personalized medicine and preventive care is contributing to the growth of the market. Although challenges such as high treatment costs and a limited patient population remain, the ongoing innovation in treatment options and expanding market access are expected to sustain the market's growth in the coming years.

Impact

  • Increasing demand for hereditary angioedema therapies is anticipated to support the growth of the global hereditary angioedema market during the forecast period 2025-2035.
  • The global hereditary angioedema market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Market Segmentation:

Segmentation 1: by Therapy Type

  • C1-esterase inhibitor
  • Bradykinin B2 receptor antagonist
  • Kallikrein inhibitor
  • Others

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

North America is expected to dominate the global hereditary angioedema market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hereditary angioedema market.

Recent Developments

  • Regulatory Activities: In February 2025, EMA approved an additional 2 mL pre-filled pen option for TAKHZYRO (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (HAE).
  • Regulatory Activities: In February 2025, CSL Behring secured regulatory approval in Japan for Andembry (garadacimab) subcutaneous injection 200mg Pens for the prevention of acute hereditary angioedema attacks.
  • Regulatory Activities: In January 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to KalVista Pharmaceuticals, Inc.'s sebetralstat.
  • Regulatory Activities: In November 2024, the FDA accepted the new drug application for Ionis Pharmaceuticals' donidalorsen for the prophylactic treatment of hereditary angioedema.

Demand - Drivers and Limitations

The following are the drivers for the global hereditary angioedema market:

  • Increasing Awareness and Early Diagnosis
  • Continuous Advancements in Treatment Options
  • Improved Genetic Testing and Diagnosis
  • Increasing Prevalence of Hereditary Angioedema

The global hereditary angioedema market is expected to face some limitations, too, due to the following challenges:

  • High Treatment Costs
  • Challenges in Accessing Treatments in Developing Regions

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hereditary angioedema market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Ionis Pharmaceutical, Takeda, and CSL Behring, have been involved in the development of therapies for hereditary angioedema.

Competitive Strategy: Enterprises led by market leaders in the global hereditary angioedema market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Adverum Biotechnologies, Inc.
  • Attune Pharmaceuticals
  • BioCryst Pharmaceuticals
  • CSL Behring
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals
  • Octapharma
  • Pharming Group
  • Takeda Pharmaceutical Company Limited

Table of Contents

Executive Summary

Scope of Study

1. Global Hereditary Angioedema Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
  • 1.2 Market Trends
  • 1.3 Epidemiological Analysis of Hereditary Angioedema
    • 1.3.1 By Region
  • 1.4 Clinical Trials
    • 1.4.1 By Phase
    • 1.4.2 By Sponsor Type
  • 1.5 Regulatory Landscape / Compliance
    • 1.5.1 Legal Requirement and Framework in the U.S.
    • 1.5.2 Legal Requirement and Framework in the E.U.
    • 1.5.3 Legal Requirement and Framework in Asia-Pacific
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Hereditary Angioedema Market, By Therapy Type, $Million, 2023-2035

  • 2.1 C1-esterase inhibitor
  • 2.2 Bradykinin B2 receptor antagonist
  • 2.3 Kallikrein inhibitor
  • 2.4 Others

3. Global Hereditary Angioedema Market, By Region, $Million, 2023-2035

  • 3.1 North America
    • 3.1.1 Market Dynamics
    • 3.1.2 Market Sizing and Forecast
      • 3.1.2.1 North America Hereditary Angioedema Market (by Country)
        • 3.1.2.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Market Dynamics
    • 3.2.2 Market Sizing and Forecast
      • 3.2.2.1 Europe Hereditary Angioedema Market (by Country)
        • 3.2.2.1.1 U.K.
        • 3.2.2.1.2 Germany
        • 3.2.2.1.3 France
        • 3.2.2.1.4 Italy
        • 3.2.2.1.5 Spain
  • 3.3 Asia-Pacific
    • 3.3.1 Market Dynamics
    • 3.3.2 Market Sizing and Forecast
      • 3.3.2.1 Asia-Pacific Hereditary Angioedema Market (by Country)
        • 3.3.2.1.1 Japan

4. Global Hereditary Angioedema Market - Competitive Benchmarking and Company Profiles

  • 4.1 Competitive Landscape
    • 4.1.1 Key Strategies and Developments by Company
      • 4.1.1.1 Funding Activities
      • 4.1.1.2 Mergers and Acquisitions
      • 4.1.1.3 Regulatory Approvals
      • 4.1.1.4 Partnerships, Collaborations and Business Expansions
    • 4.1.2 Key Developments Analysis
  • 4.2 Company Profiles
    • 4.2.1 Takeda Pharmaceutical Company Limited
      • 4.2.1.1 Company Overview
      • 4.2.1.2 Product Portfolio
      • 4.2.1.3 Target Customers/End Users
      • 4.2.1.4 Analyst View
    • 4.2.2 CSL Behring
      • 4.2.2.1 Company Overview
      • 4.2.2.2 Product Portfolio
      • 4.2.2.3 Target Customers/End Users
      • 4.2.2.4 Analyst View
    • 4.2.3 Ionis Pharmaceuticals, Inc.
      • 4.2.3.1 Company Overview
      • 4.2.3.2 Product Portfolio
      • 4.2.3.3 Target Customers/End Users
      • 4.2.3.4 Analyst View
    • 4.2.4 Pharming Group
      • 4.2.4.1 Company Overview
      • 4.2.4.2 Product Portfolio
      • 4.2.4.3 Target Customers/End Users
      • 4.2.4.4 Analyst View
    • 4.2.5 BioCryst Pharmaceuticals
      • 4.2.5.1 Company Overview
      • 4.2.5.2 Product Portfolio
      • 4.2.5.3 Target Customers/End Users
      • 4.2.5.4 Analyst View
    • 4.2.6 KalVista Pharmaceuticals
      • 4.2.6.1 Company Overview
      • 4.2.6.2 Product Portfolio
      • 4.2.6.3 Target Customers/End Users
      • 4.2.6.4 Analyst View
    • 4.2.7 Attune Pharmaceuticals
      • 4.2.7.1 Company Overview
      • 4.2.7.2 Product Portfolio
      • 4.2.7.3 Target Customers/End Users
      • 4.2.7.4 Analyst View
    • 4.2.8 Adverum Biotechnologies, Inc.
      • 4.2.8.1 Company Overview
      • 4.2.8.2 Product Portfolio
      • 4.2.8.3 Target Customers/End Users
      • 4.2.8.4 Analyst View
    • 4.2.9 Octapharma
      • 4.2.9.1 Company Overview
      • 4.2.9.2 Product Portfolio
      • 4.2.9.3 Target Customers/End Users
      • 4.2.9.4 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Hereditary Angioedema Market, Epidemiological Analysis, U.S.
  • Figure: Global Hereditary Angioedema Market Coverage
  • Figure: Global Hereditary Angioedema Market Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Hereditary Angioedema Market, Competitive Landscape, January 2022-April 2025

List of Tables

  • Table: Global Hereditary Angioedema Market, Regulatory Scenario
  • Table: Global Hereditary Angioedema Market Dynamics, Impact Analysis
  • Table: Global Hereditary Angioedema Market (by Therapy Type), $Million, 2023-2035
  • Table: Global Hereditary Angioedema Market (by Region), $Million, 2023-2035